196 related articles for article (PubMed ID: 36557281)
1. Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Theofilis P; Vordoni A; Kalaitzidis RG
Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557281
[TBL] [Abstract][Full Text] [Related]
2. Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease.
Flores-Guerrero JL; Post A; van Dijk PR; Connelly MA; Garcia E; Navis G; Bakker SJL; Dullaart RPF
Liver Int; 2021 Oct; 41(10):2371-2382. PubMed ID: 33993608
[TBL] [Abstract][Full Text] [Related]
3. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.
Chen YM; Liu Y; Zhou RF; Chen XL; Wang C; Tan XY; Wang LJ; Zheng RD; Zhang HW; Ling WH; Zhu HL
Sci Rep; 2016 Jan; 6():19076. PubMed ID: 26743949
[TBL] [Abstract][Full Text] [Related]
4. Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease.
Moradzad M; Abdi M; Sheikh Esmaeili F; Ghaderi D; Rahmani K; Moloudi MR; Vahabzadeh Z
Mol Biol Rep; 2022 Jul; 49(7):5927-5937. PubMed ID: 35348964
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke: a systematic review and dose-response meta-analysis.
Farhangi MA; Vajdi M; Asghari-Jafarabadi M
Nutr J; 2020 Jul; 19(1):76. PubMed ID: 32731904
[TBL] [Abstract][Full Text] [Related]
6. Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine.
Shi C; Pei M; Wang Y; Chen Q; Cao P; Zhang L; Guo J; Deng W; Wang L; Li X; Gong Z
Biochem Biophys Res Commun; 2022 Feb; 594():1-7. PubMed ID: 35065293
[TBL] [Abstract][Full Text] [Related]
7. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO).
Barrea L; Muscogiuri G; Annunziata G; Laudisio D; de Alteriis G; Tenore GC; Colao A; Savastano S
Nutrients; 2019 Jun; 11(6):. PubMed ID: 31185686
[No Abstract] [Full Text] [Related]
8. A systematic review and meta-analysis of the gut microbiota-dependent metabolite trimethylamine N-oxide with the incidence of atrial fibrillation.
Yang WT; Yang R; Zhao Q; Li XD; Wang YT
Ann Palliat Med; 2021 Nov; 10(11):11512-11523. PubMed ID: 34872276
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro.
Nian F; Zhu C; Jin N; Xia Q; Wu L; Lu X
Biochem Biophys Res Commun; 2023 Aug; 669():134-142. PubMed ID: 37271025
[TBL] [Abstract][Full Text] [Related]
10. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
[TBL] [Abstract][Full Text] [Related]
11. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.
León-Mimila P; Villamil-Ramírez H; Li XS; Shih DM; Hui ST; Ocampo-Medina E; López-Contreras B; Morán-Ramos S; Olivares-Arevalo M; Grandini-Rosales P; Macías-Kauffer L; González-González I; Hernández-Pando R; Gómez-Pérez F; Campos-Pérez F; Aguilar-Salinas C; Larrieta-Carrasco E; Villarreal-Molina T; Wang Z; Lusis AJ; Hazen SL; Huertas-Vazquez A; Canizales-Quinteros S
Diabetes Metab; 2021 Mar; 47(2):101183. PubMed ID: 32791310
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) potentially increases the risk of obesity in adults: An exploratory systematic review and dose-response meta- analysis.
Dehghan P; Farhangi MA; Nikniaz L; Nikniaz Z; Asghari-Jafarabadi M
Obes Rev; 2020 May; 21(5):e12993. PubMed ID: 32017391
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the impact of bariatric surgery on circulating TMAO levels as a predictor of cardiovascular disease risk.
Jamialahmadi T; Simental-Mendia LE; Zengin G; Almahmeed W; Kesharwani P; Sahebkar A
Curr Med Chem; 2023 May; ():. PubMed ID: 37226793
[TBL] [Abstract][Full Text] [Related]
14. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Polyzos SA; Aronis KN; Kountouras J; Raptis DD; Vasiloglou MF; Mantzoros CS
Diabetologia; 2016 Jan; 59(1):30-43. PubMed ID: 26407715
[TBL] [Abstract][Full Text] [Related]
15. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis.
Li F; Ye J; Shao C; Zhong B
Lipids Health Dis; 2021 Feb; 20(1):22. PubMed ID: 33637088
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota-dependent trimethylamine N-oxide and all-cause mortality: Findings from an updated systematic review and meta-analysis.
Farhangi MA
Nutrition; 2020 Oct; 78():110856. PubMed ID: 32592979
[TBL] [Abstract][Full Text] [Related]
17. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
18. The Gut Microbial Metabolite Trimethylamine N-Oxide is Linked to Specific Complications of Systemic Sclerosis.
Stec A; Maciejewska M; Paralusz-Stec K; Michalska M; Giebułtowicz J; Rudnicka L; Sikora M
J Inflamm Res; 2023; 16():1895-1904. PubMed ID: 37152867
[TBL] [Abstract][Full Text] [Related]
19. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: A systematic review and dose-response meta-analysis.
Zhuang R; Ge X; Han L; Yu P; Gong X; Meng Q; Zhang Y; Fan H; Zheng L; Liu Z; Zhou X
Obes Rev; 2019 Jun; 20(6):883-894. PubMed ID: 30868721
[TBL] [Abstract][Full Text] [Related]
20. Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Theofilis P; Vordoni A; Nakas N; Kalaitzidis RG
Life (Basel); 2022 May; 12(5):. PubMed ID: 35629385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
